EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.
Issue link: https://digital.eyeworld.org/i/78721
January 2012 EWInternational 57 Figure 2 Figure 1 Dr. De La Peña: Are the rates of possible visual complaints such as halos, glare, or dysphotopsias similar to those found in the U.S. or Europe? Dr. Suárez: I think that they are similar. The ac- ceptance and tolerance of these disturbances will depend on how the procedure was discussed with the patient during the pre-op "chair time" and how motivated the patient is to be able to read without the aid of spectacles. Dr. Carreño: It is difficult to answer that ques- tion, since the reports worldwide about halos and glare are extremely varied. In my personal experi- ence, about 35% of the patients with multifocal im- plantations spontaneously reported halos when driving at night, even though they usually decrease progressively and eventually disappear after 6 months. In order to prevent post-op dissatisfaction I think that it is of the greatest importance to advise and inform the patient about the possibility of some visual disturbances during the first months after surgery. Dr. Centurion: When patients are chosen for implantation of multifocal IOLs, we always advise the patients about the possible collateral effects of surgery regarding quality of visual acuity such as halos, glare, dysphotopsias, decreased contrast sen- sitivity (especially under mesopic conditions), and difficult near vision in twilight, and that these pos- sible disturbances are almost always temporary. In my personal experience, glare complaints do not exist, and halos, when present, do not justify complaints after 8 to 12 weeks. I think that, following an appropriate patient selection, and especially if biometry showed a pre- dictable refraction, the satisfaction index is ex- tremely high. I think that it is very important for the surgeon to be able to say, "In your case I would not indicate a multifocal IOL for the following reasons ..." It is prevention of complications. EW Editors' note: Dr. Carreño has no related financial interests. Dr. Centurion has financial interests with Alcon. Dr. Suárez has no financial interests related to this roundtable. Contact information Carreño: edcarreno@vtr.net Centurion: centurion@imo.com.br Suárez: ensuca@gmail.com Figure 4 Figure 3